How to Taper Off Semaglutide and Tirzepatide Safely: The Discontinuation Protocol Guide

There is no FDA-approved tapering schedule for semaglutide or tirzepatide. The Wegovy and Zepbound prescribing information both treat discontinuation as “simply stop” [4, 5]. But the clinical reality is more complicated: the STEP-4 trial [1] showed that patients who stopped semaglutide at week 20 regained roughly 67% of the lost weight within a year, and the SURMOUNT-4 trial [3] showed a nearly identical rebound pattern for tirzepatide. This is not a failure of willpower — it's a documented physiological rebound driven by the same appetite and energy-expenditure mechanisms the drug was suppressing. This guide walks through the evidence-based options: continuing at maintenance (the trial-supported protocol), stepping down to a lower dose (off-label but increasingly used), or full discontinuation with a lifestyle bridge plan. Any actual tapering or discontinuation decision belongs with your prescriber.

What STEP-4 and SURMOUNT-4 actually showed

STEP-4 (Rubino et al., JAMA 2021 [1]) was the landmark maintenance trial for semaglutide. The design:

• All participants started on semaglutide 2.4 mg and completed the standard 20-week titration ramp
• At week 20, participants were randomized to either continue semaglutide 2.4 mg for an additional 48 weeks, or switch to placebo
• The primary endpoint was percent change in body weight from week 20 to week 68

The results [1]:

The between-group difference was approximately 14.8 percentage points [1]. On the regain side, patients in the placebo arm regained most of their initial weight loss over the following 48 weeks — ending the trial with essentially the same weight they had at randomization, or slightly heavier. The trial extension data (Wilding et al., DOM 2022 [2]) followed patients out further and showed approximately 67% of the original weight loss had been regained within one year of discontinuation.

SURMOUNT-4 (Aronne et al., JAMA 2024 [3]) replicated this pattern for tirzepatide. Patients who completed the 36-week titration + early-maintenance phase and then switched to placebo regained approximately 14 percentage points of body weight, while patients who continued tirzepatide lost an additional 5.5 percentage points. The conclusion from both trials is consistent: GLP-1 therapy works for as long as you take it, and the weight comes back when you stop.

Why weight rebounds after stopping

Three overlapping physiological mechanisms drive the rebound [1, 2, 3]:

1. Appetite returns to baseline within weeks. Semaglutide has a 7-day half-life and tirzepatide has a 5-day half-life. After discontinuation, plasma levels drop to zero within 4-5 weeks, and the appetite- suppression effect goes with them. Patients typically report feeling “normal hunger” again by weeks 4-6 post-discontinuation.
2. Resting metabolic rate adapted during weight loss. Rapid weight loss from any cause produces adaptive metabolic compensation — the body burns fewer calories at rest after losing weight than before. This effect is well-documented across diet, surgery, and drug interventions. When appetite returns to pre-therapy levels but metabolic rate stays suppressed, the caloric balance tips toward regain.
3. Hormonal set-point pressure. Ghrelin, leptin, and other appetite hormones shift toward “defend the higher weight” after loss. GLP-1 therapy masks this pressure while it's active; stopping unmasks it. The set-point biology is the same in all successful weight-loss interventions and is the main reason “just eat less” doesn't work long-term for most patients.

The bottom line: rebound after GLP-1 discontinuation is biological, not behavioral. Patients who rebound are not failing — their physiology is doing exactly what the trial data predicts.

Option 1: Continue at maintenance dose (the trial-supported protocol)

This is the only protocol with direct trial evidence. The STEP-4 and SURMOUNT-4 continuation arms show that patients who stay on the maintenance dose continue to lose weight slowly and maintain the loss indefinitely [1, 3]. Both the Wegovy and Zepbound labels position the drugs as chronic weight management, meaning long-term use — not a course of treatment with a defined end.

Practical considerations for continuing indefinitely:

• Continued cost — whether brand-name insurance coverage, compounded vial pricing, or the new Foundayo $149/month option
• Ongoing GI side-effect management — most patients tolerate maintenance dose long-term with minimal residual nausea
• Long-term safety monitoring — annual review of gallbladder, thyroid, pancreatitis risk factors
• Lean-mass preservation — protein targets and resistance training matter more during long-term use, not less

If you are on GLP-1 therapy and achieving your weight loss goals with tolerable side effects, the trial-supported answer is: don't stop. This is the position of both the Wegovy and Zepbound FDA labels [4, 5] and of most obesity-medicine specialists.

Option 2: Step down to a lower dose (off-label, unstudied)

An increasingly common off-label practice: instead of stopping entirely, patients step their dose down from maintenance to a lower level (e.g. from 2.4 mg semaglutide to 1 mg, or from 15 mg tirzepatide to 7.5 mg) in the hope of maintaining most of the weight loss at lower cost and lower side-effect burden.

There is no published trial evidence for this protocol. The STEP-4 and SURMOUNT-4 trials did not include a step-down arm. Anecdotally, some patients do maintain their weight at lower doses for months to years, while others experience gradual regain. The dose-response data from STEP-1 suggests lower doses produce lower appetite-suppression effect, which implies some rebound is likely, but the specific maintenance-at-lower-dose experience is an evidence vacuum.

Why patients try it anyway:

• Cost reduction. A lower dose means the vial lasts longer, which directly reduces monthly expense.
• Side effect tolerance. Patients who had significant GI symptoms at maintenance often tolerate lower doses better.
• Perceived long-term safety. Less drug = perceived less risk, though the trial safety data does not directly support this intuition.

If you and your prescriber decide to try a step-down approach, the practical pattern most clinicians use:

1. Drop one dose level (for example, 2.4 mg semaglutide → 1.7 mg). Stay at that dose for 4-8 weeks.
2. Monitor weight closely — weekly weigh-ins rather than monthly.
3. If weight is stable at the new dose for 8+ weeks, consider staying there. If weight is creeping up, either return to the previous dose or accept the slow regain.
4. Re-evaluate every 3 months with your prescriber.

For more on the specific evidence (and evidence vacuum) around sub-therapeutic dosing, see our microdosing evidence guide.

Option 3: Full discontinuation with a lifestyle bridge

If you're going to stop entirely, the STEP-4 data [1] is unambiguous: expect rebound. The question is how to minimize it. The trial data does not support any specific lifestyle intervention that fully prevents rebound, but general weight-loss maintenance literature suggests the following improve odds of maintaining more of the loss:

1. Don't stop at a dose above your long-term target weight. If you stop while still losing, you will regain to somewhere above your nadir. Plan the stop for after you have reached a weight you are willing to return to.
2. Stabilize for 4-8 weeks at the target weight on the drug before stopping. This gives your body time to adapt to the lower weight before the drug is removed.
3. Have a caloric target in place before you stop. The appetite suppression is about to return to baseline. A sustainable 500-750 kcal/day caloric deficit plan, pre-calculated, with specific meal templates, is the single most-studied maintenance intervention.
4. Maintain resistance training and high protein. Both improve post-discontinuation outcomes by preserving lean mass and improving metabolic rate. See our muscle mass deep-dive and our diet guide.
5. Weigh yourself daily. Early detection of regain is critical. If you're up 5 lbs from nadir within 4 weeks of stopping, talk to your prescriber about resuming therapy before the rebound compounds.
6. Know the resumption option. Stopping is not one-way. If the rebound proves intolerable, you can restart semaglutide or tirzepatide. The re-titration takes the standard 16-20 weeks and you should expect to lose the regained weight over a similar timeline.

Medical reasons to actually stop

A subset of patients have clinical reasons to discontinue that override the rebound concern:

• Pregnancy or trying to conceive. Both Wegovy and Zepbound labels recommend discontinuing at least 2 months before planned conception [4, 5]. The drugs are contraindicated during pregnancy.
• Pancreatitis. Acute pancreatitis is a boxed warning on the class and is a hard stop — do not resume.
• Gallbladder surgery. The drugs increase gallbladder-disease risk and are typically held perioperatively.
• Severe diabetic retinopathy progression in T2D patients on Ozempic/Mounjaro.
• Gastroparesis or severe reflux that does not resolve with dose reduction.
• Scheduled surgery or deep sedation. The GLP-1 labels recommend holding the drug before procedures with anesthesia because of aspiration risk from delayed gastric emptying.

In these cases, the discontinuation is clinically driven and the rebound concern is secondary. Your prescriber will manage the transition.

The decision framework

A practical framework for the stop-or-continue decision:

1. Is there a medical reason to stop? If yes, stop under prescriber supervision and manage the rebound downstream. This is a non-negotiable clinical decision.
2. Are you at a stable goal weight with tolerable side effects? If yes, the trial-supported answer is to continue at maintenance dose indefinitely [1, 3].
3. Is cost the primary obstacle? Before stopping, explore lower-cost options: compounded vials, Foundayo $149/month, or the brand-name patient assistance programs. See our pricing index.
4. Are side effects the primary obstacle? Try a dose step-down first (Option 2), or switch to a different GLP-1 (see our switching guide) before discontinuing entirely.
5. Have you truly decided you want to stop? Then plan the full-discontinuation protocol with your prescriber at least 1-2 months in advance of the stop date. Do not stop cold on a whim.

What to call your prescriber about

Before stopping, call your prescriber if:

• You're considering discontinuation for any reason — the conversation should happen before the last dose, not after
• You're experiencing side effects you can't tolerate (there may be management options short of stopping)
• Cost has become prohibitive (there are often prescriber-side options to reduce cost)
• You're pregnant or planning pregnancy
• You're scheduled for surgery within the next 4 weeks
• You've already stopped and are experiencing rapid rebound — resuming sooner is easier than later

Important disclaimer

This article is educational and summarizes the STEP-4 and SURMOUNT-4 published trial data along with general clinical practice patterns. It is not a dose recommendation and does not constitute medical advice. Any decision to stop, step down, or continue GLP-1 therapy belongs between you and your prescriber. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment recommendations.

Related research and tools

For the full STEP-4 deep-dive on what happens after discontinuation, see our post-discontinuation guide. For switching to a different GLP-1 instead of stopping, see our switching guide. For step-down dosing considerations, see our microdosing evidence guide. For the expected weight trajectory on each drug, use our weight loss calculator. For the lean-mass preservation protocol, see our muscle mass deep-dive.